Latest news with #RocheDiagnostics
Yahoo
4 days ago
- Business
- Yahoo
Epigenetics Diagnostics Market Analysis 2025-2034: Oncology Led with 68.7% Share in 2024, Driven by Demand for Early and Precise Cancer Detection Through Epigenetic Markers
The market, dominated by DNA methylation, sees significant contributions from North America, with the U.S. leading. Major players include Thermo Fisher Scientific, Illumina, and Roche Diagnostics, focusing on innovative tools that enhance precision medicine. Epigenetics Diagnostics Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 70.7 billion by 2034. The market is gaining momentum due to the rising awareness of how epigenetic mechanisms contribute to disease development, especially in complex and chronic conditions. The continuous evolution of diagnostic technologies is another key factor driving growth. Increasing cases of chronic illnesses and cancer globally have created a pressing demand for early and accurate detection methods. This, in turn, has fueled the need for advanced epigenetic biomarkers and testing assays. Additionally, the expanding use of next-generation sequencing technologies and AI-powered analytics has significantly improved the efficiency and scalability of epigenetic diagnostics. The growing preference for non-invasive procedures like liquid biopsies has further encouraged market adoption. Collaborations among pharmaceutical manufacturers, research bodies, and diagnostics firms are increasing to develop safer and more effective diagnostic tools. These initiatives are helping accelerate the transition of epigenetic diagnostics from research labs to mainstream clinical use. With heightened interest in precision medicine, the industry is seeing a sharp focus on the development of highly accurate and scalable solutions that support early intervention and personalized treatment market centers on technologies used to detect and analyze epigenetic markers, including DNA methylation and histone modifications, which are pivotal in identifying disease risks and progression. These diagnostics offer valuable insights for early-stage diagnosis and treatment planning across a range of conditions, including cancer and neurological disorders. Based on product type, the market is segmented into instruments, kits and reagents, and software and services. In 2024, the kits and reagents category led the market with a valuation of USD 7.6 billion. These products are integral to routine diagnostic workflows and are extensively used in clinical settings, academic research, and pharmaceutical development. Their ease of use, reliability, and compatibility with automated and high-throughput systems such as PCR and sequencing platforms make them widely preferred. Continuous improvements in assay sensitivity and integration with advanced technologies are driving further adoption. Additionally, the increasing emphasis on environmentally sustainable and cost-effective reagent development has enhanced accessibility, particularly in developing terms of application, the epigenetics diagnostics market is split between oncology and non-oncology diagnostics. The oncology diagnostics segment commanded a dominant share of 68.7% in 2024. This growth is propelled by the demand for early and precise cancer detection using epigenetic markers. DNA methylation and histone changes are commonly linked to various forms of cancer and serve as effective indicators for early diagnosis. The rising number of cancer cases, coupled with the shift toward personalized therapies, has heightened interest in epigenetic diagnostics. Awareness campaigns and initiatives promoting early detection and treatment are also playing a pivotal role in expanding this on technology, the market includes DNA methylation, histone methylation, microRNA modification, chromatin structure analysis, and other methods. DNA methylation dominated the landscape with a value of USD 6.3 billion in 2024 and is projected to reach USD 28.5 billion by 2034. This segment's strength lies in its capacity to identify disease-specific methylation markers, enabling earlier and more accurate diagnoses. Techniques like bisulfite sequencing, methylation-specific PCR, and array-based assays have advanced the precision of methylation studies, allowing for more effective disease monitoring. Integration of these methods with next-generation sequencing tools continues to improve test sensitivity and throughput, making them increasingly valuable in both research and clinical end user, the market is divided into hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Hospitals and clinics led the market in 2024 and are expected to reach USD 25.9 billion by 2034. These institutions play a vital role in deploying epigenetic testing for diagnostics, prognosis, and treatment monitoring. Their infrastructure and expertise allow for comprehensive testing and interpretation, including genetic counseling and interdisciplinary collaboration. The trend toward precision medicine has further boosted demand within hospitals, which often serve as central hubs for patient care and advanced North America held the largest share in 2024, accounting for 39.7% of the global market. The U.S. alone was valued at USD 5.4 billion in the same year. Factors contributing to the region's dominance include robust healthcare infrastructure, high investments in genomic research, and increased adoption of precision diagnostics. Government initiatives and funding support, especially from research bodies, have helped accelerate innovation in epigenetics. The growing burden of chronic diseases and a strong emphasis on non-invasive diagnostics continue to propel demand in the companies - Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Roche Diagnostics - collectively held around 65% of the market share. These firms stay ahead through continuous innovations in sequencing systems, methylation detection tools, and integrated bioinformatics. Their expanding portfolios, including single-cell analysis and targeted panels, align with the rising demand for tailored diagnostic Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 133 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $15.5 Billion Forecasted Market Value (USD) by 2034 $70.7 Billion Compound Annual Growth Rate 16.5% Regions Covered Global Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Increasing prevalence of cancer and chronic diseases3.2.1.2 Advancements in epigenomics research and technology3.2.1.3 Growing demand for non-invasive diagnostics3.2.2 Industry pitfalls and challenges3.2.2.1 High cost of epigenetic diagnostics technologies3.2.2.2 Limited standardization of testing methods3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Retaliatory measures3.5.2 Impact on the Industry3.5.2.1 Supply-side impact (raw materials)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (selling price)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Kits and reagents5.3 Instruments5.4 Software and servicesChapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Oncology diagnostics6.3 Non-oncology diagnosticsChapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)7.1 Key trends7.2 DNA methylation7.3 Histone methylation7.4 MicroRNA modification7.5 Chromatin structures7.6 Other technologiesChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Hospital and clinics8.3 Pharmaceutical and biotechnology companies8.4 Diagnostic laboratories8.5 Other end useChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Netherlands9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.4.4 Australia9.4.5 South Korea9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.5.3 Argentina9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia9.6.3 UAEChapter 10 Company Profiles10.1 Abcam10.2 Agilent Technologies10.3 Diagenode10.4 Dovetail Genomics10.5 Element Biosciences10.6 Illumina10.7 Merck10.8 New England Biolabs10.9 PacBio10.10 Promega10.11 QIAGEN10.12 Roche Diagnostics10.13 Thermo Fisher Scientific10.14 Zymo Research For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epigenetics Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Epigenetics Diagnostics Market Analysis 2025-2034: Oncology Led with 68.7% Share in 2024, Driven by Demand for Early and Precise Cancer Detection Through Epigenetic Markers
The market, dominated by DNA methylation, sees significant contributions from North America, with the U.S. leading. Major players include Thermo Fisher Scientific, Illumina, and Roche Diagnostics, focusing on innovative tools that enhance precision medicine. Epigenetics Diagnostics Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 70.7 billion by 2034. The market is gaining momentum due to the rising awareness of how epigenetic mechanisms contribute to disease development, especially in complex and chronic conditions. The continuous evolution of diagnostic technologies is another key factor driving growth. Increasing cases of chronic illnesses and cancer globally have created a pressing demand for early and accurate detection methods. This, in turn, has fueled the need for advanced epigenetic biomarkers and testing assays. Additionally, the expanding use of next-generation sequencing technologies and AI-powered analytics has significantly improved the efficiency and scalability of epigenetic diagnostics. The growing preference for non-invasive procedures like liquid biopsies has further encouraged market adoption. Collaborations among pharmaceutical manufacturers, research bodies, and diagnostics firms are increasing to develop safer and more effective diagnostic tools. These initiatives are helping accelerate the transition of epigenetic diagnostics from research labs to mainstream clinical use. With heightened interest in precision medicine, the industry is seeing a sharp focus on the development of highly accurate and scalable solutions that support early intervention and personalized treatment market centers on technologies used to detect and analyze epigenetic markers, including DNA methylation and histone modifications, which are pivotal in identifying disease risks and progression. These diagnostics offer valuable insights for early-stage diagnosis and treatment planning across a range of conditions, including cancer and neurological disorders. Based on product type, the market is segmented into instruments, kits and reagents, and software and services. In 2024, the kits and reagents category led the market with a valuation of USD 7.6 billion. These products are integral to routine diagnostic workflows and are extensively used in clinical settings, academic research, and pharmaceutical development. Their ease of use, reliability, and compatibility with automated and high-throughput systems such as PCR and sequencing platforms make them widely preferred. Continuous improvements in assay sensitivity and integration with advanced technologies are driving further adoption. Additionally, the increasing emphasis on environmentally sustainable and cost-effective reagent development has enhanced accessibility, particularly in developing terms of application, the epigenetics diagnostics market is split between oncology and non-oncology diagnostics. The oncology diagnostics segment commanded a dominant share of 68.7% in 2024. This growth is propelled by the demand for early and precise cancer detection using epigenetic markers. DNA methylation and histone changes are commonly linked to various forms of cancer and serve as effective indicators for early diagnosis. The rising number of cancer cases, coupled with the shift toward personalized therapies, has heightened interest in epigenetic diagnostics. Awareness campaigns and initiatives promoting early detection and treatment are also playing a pivotal role in expanding this on technology, the market includes DNA methylation, histone methylation, microRNA modification, chromatin structure analysis, and other methods. DNA methylation dominated the landscape with a value of USD 6.3 billion in 2024 and is projected to reach USD 28.5 billion by 2034. This segment's strength lies in its capacity to identify disease-specific methylation markers, enabling earlier and more accurate diagnoses. Techniques like bisulfite sequencing, methylation-specific PCR, and array-based assays have advanced the precision of methylation studies, allowing for more effective disease monitoring. Integration of these methods with next-generation sequencing tools continues to improve test sensitivity and throughput, making them increasingly valuable in both research and clinical end user, the market is divided into hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Hospitals and clinics led the market in 2024 and are expected to reach USD 25.9 billion by 2034. These institutions play a vital role in deploying epigenetic testing for diagnostics, prognosis, and treatment monitoring. Their infrastructure and expertise allow for comprehensive testing and interpretation, including genetic counseling and interdisciplinary collaboration. The trend toward precision medicine has further boosted demand within hospitals, which often serve as central hubs for patient care and advanced North America held the largest share in 2024, accounting for 39.7% of the global market. The U.S. alone was valued at USD 5.4 billion in the same year. Factors contributing to the region's dominance include robust healthcare infrastructure, high investments in genomic research, and increased adoption of precision diagnostics. Government initiatives and funding support, especially from research bodies, have helped accelerate innovation in epigenetics. The growing burden of chronic diseases and a strong emphasis on non-invasive diagnostics continue to propel demand in the companies - Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Roche Diagnostics - collectively held around 65% of the market share. These firms stay ahead through continuous innovations in sequencing systems, methylation detection tools, and integrated bioinformatics. Their expanding portfolios, including single-cell analysis and targeted panels, align with the rising demand for tailored diagnostic Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 133 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $15.5 Billion Forecasted Market Value (USD) by 2034 $70.7 Billion Compound Annual Growth Rate 16.5% Regions Covered Global Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Increasing prevalence of cancer and chronic diseases3.2.1.2 Advancements in epigenomics research and technology3.2.1.3 Growing demand for non-invasive diagnostics3.2.2 Industry pitfalls and challenges3.2.2.1 High cost of epigenetic diagnostics technologies3.2.2.2 Limited standardization of testing methods3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Retaliatory measures3.5.2 Impact on the Industry3.5.2.1 Supply-side impact (raw materials)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (selling price)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Kits and reagents5.3 Instruments5.4 Software and servicesChapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Oncology diagnostics6.3 Non-oncology diagnosticsChapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)7.1 Key trends7.2 DNA methylation7.3 Histone methylation7.4 MicroRNA modification7.5 Chromatin structures7.6 Other technologiesChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Hospital and clinics8.3 Pharmaceutical and biotechnology companies8.4 Diagnostic laboratories8.5 Other end useChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Netherlands9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.4.4 Australia9.4.5 South Korea9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.5.3 Argentina9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia9.6.3 UAEChapter 10 Company Profiles10.1 Abcam10.2 Agilent Technologies10.3 Diagenode10.4 Dovetail Genomics10.5 Element Biosciences10.6 Illumina10.7 Merck10.8 New England Biolabs10.9 PacBio10.10 Promega10.11 QIAGEN10.12 Roche Diagnostics10.13 Thermo Fisher Scientific10.14 Zymo Research For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epigenetics Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
13-06-2025
- Business
- Yahoo
Protein Chips Industry Analysis (2025-2030) Featuring Strategic Profiles of 42 Market Players Including Abcam, Agilent and Roche Diagnostics
As precision medicine rises, protein chips play a pivotal role in diagnostics and drug discovery, with applications expanding in oncology, autoimmune disorders, and environmental testing. Regionally, the U.S. market was valued at $633.4 million in 2024, while China is anticipated to grow at a 6% CAGR to $552.8 million by 2030. Major players include Abcam, Agilent, and Roche Diagnostics. Protein Chips Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Protein Chips - Global Strategic Business Report" has been added to global market for Protein Chips was valued at US$2.4 Billion in 2024 and is projected to reach US$3.4 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Protein Chips market. The growth in the protein chips market is driven by several factors stemming from advancements in microarray technology, broader end-use applications, and increased demand for personalized medicine. Technologically, innovations in signal detection, miniaturization, and chip reproducibility are making protein chips more powerful and accessible. End-use growth is seen in pharmaceutical R&D, molecular diagnostics, and point-of-care testing, where fast and multiplexed protein analysis is critical. Consumers especially in wellness and genomics are also driving demand for individualized proteomic data, supporting use cases in preventive healthcare. Further, the expansion of proteomics infrastructure in Asia-Pacific and increased public-private research funding are contributing to the global scaling of protein chip manufacturing and adoption. These converging trends are establishing protein chips as a linchpin technology in modern biomedical research and diagnostics. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abcam plc, Agilent Technologies Inc., Arrayit Corporation, Ayoxxa Biosystems GmbH, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Analytical Microarrays segment, which is expected to reach US$1.5 Billion by 2030 with a CAGR of a 4.5%. The Functional Protein Microarrays segment is also set to grow at 8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $633.4 Million in 2024, and China, forecasted to grow at an impressive 6.0% CAGR to reach $552.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Why You Should Buy This Report: Detailed Market Analysis: Access a thorough analysis of the Global Protein Chips Market, covering all major geographic regions and market segments. Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies. Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Protein Chips Market. Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions. Key Questions Answered: How is the Global Protein Chips Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Some of the 42 companies featured in this Protein Chips market report include: Abcam plc Agilent Technologies Inc. Arrayit Corporation Ayoxxa Biosystems GmbH Bio-Rad Laboratories Inc. CDI Laboratories Inc. Danaher Corporation Full Moon BioSystems Inc. Illumina Inc. Innopsys S.A. Luminex Corporation Microarrays Inc. OriGene Technologies Inc. PerkinElmer Inc. RayBiotech Inc. Roche Diagnostics Sengenics Corporation Pte Ltd. Shimadzu Corporation Sigma-Aldrich Corporation Thermo Fisher Scientific Inc. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes Report Attribute Details No. of Pages 216 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $2.4 Billion Forecasted Market Value (USD) by 2030 $3.4 Billion Compound Annual Growth Rate 6% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Protein Chips - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Increasing Focus on Personalized Medicine Propels Demand for High-Throughput Protein Analysis Growth in Biomarker Discovery and Disease Profiling Expands Applications in Oncology and Neurology Rising Adoption of Multiplexed Assays Accelerates Use in Drug Development Pipelines Integration of AI and Machine Learning Enhances Data Interpretation and Diagnostic Accuracy Expansion of Proteomics Research in Academic Institutions Drives Product Demand Technological Advancements in Microarray Surface Chemistry Strengthen Analytical Performance Growing Prevalence of Chronic Diseases Spurs Use of Protein Chips in Clinical Diagnostics Miniaturization and Automation of Laboratory Processes Propel Adoption in Research Settings Government Funding for Life Sciences R&D Supports Market Growth Across Developed Nations Partnerships Between Biotech Firms and CROs Increase Commercialization of Custom Protein Arrays Increased Interest in Immune Profiling and Vaccine Development Boosts Segment Demand Shift Toward Point-of-Care Diagnostics Expands Use of Lab-on-a-Chip Solutions Rising Throughput Requirements in Genomic-Proteomic Integration Strengthens Market Appeal Emergence of Next-Gen Antibody-Based Chips Drives Innovation and Competitive Differentiation Regulatory Advancements and Approval Pathways Facilitate Clinical Use of Protein Microarrays For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Protein Chips Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
Protein Chips Industry Analysis (2025-2030) Featuring Strategic Profiles of 42 Market Players Including Abcam, Agilent and Roche Diagnostics
As precision medicine rises, protein chips play a pivotal role in diagnostics and drug discovery, with applications expanding in oncology, autoimmune disorders, and environmental testing. Regionally, the U.S. market was valued at $633.4 million in 2024, while China is anticipated to grow at a 6% CAGR to $552.8 million by 2030. Major players include Abcam, Agilent, and Roche Diagnostics. Protein Chips Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Protein Chips - Global Strategic Business Report" has been added to global market for Protein Chips was valued at US$2.4 Billion in 2024 and is projected to reach US$3.4 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Protein Chips market. The growth in the protein chips market is driven by several factors stemming from advancements in microarray technology, broader end-use applications, and increased demand for personalized medicine. Technologically, innovations in signal detection, miniaturization, and chip reproducibility are making protein chips more powerful and accessible. End-use growth is seen in pharmaceutical R&D, molecular diagnostics, and point-of-care testing, where fast and multiplexed protein analysis is critical. Consumers especially in wellness and genomics are also driving demand for individualized proteomic data, supporting use cases in preventive healthcare. Further, the expansion of proteomics infrastructure in Asia-Pacific and increased public-private research funding are contributing to the global scaling of protein chip manufacturing and adoption. These converging trends are establishing protein chips as a linchpin technology in modern biomedical research and diagnostics. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abcam plc, Agilent Technologies Inc., Arrayit Corporation, Ayoxxa Biosystems GmbH, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Analytical Microarrays segment, which is expected to reach US$1.5 Billion by 2030 with a CAGR of a 4.5%. The Functional Protein Microarrays segment is also set to grow at 8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $633.4 Million in 2024, and China, forecasted to grow at an impressive 6.0% CAGR to reach $552.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Why You Should Buy This Report: Detailed Market Analysis: Access a thorough analysis of the Global Protein Chips Market, covering all major geographic regions and market segments. Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies. Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Protein Chips Market. Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions. Key Questions Answered: How is the Global Protein Chips Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Some of the 42 companies featured in this Protein Chips market report include: Abcam plc Agilent Technologies Inc. Arrayit Corporation Ayoxxa Biosystems GmbH Bio-Rad Laboratories Inc. CDI Laboratories Inc. Danaher Corporation Full Moon BioSystems Inc. Illumina Inc. Innopsys S.A. Luminex Corporation Microarrays Inc. OriGene Technologies Inc. PerkinElmer Inc. RayBiotech Inc. Roche Diagnostics Sengenics Corporation Pte Ltd. Shimadzu Corporation Sigma-Aldrich Corporation Thermo Fisher Scientific Inc. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes Report Attribute Details No. of Pages 216 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $2.4 Billion Forecasted Market Value (USD) by 2030 $3.4 Billion Compound Annual Growth Rate 6% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Protein Chips - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Increasing Focus on Personalized Medicine Propels Demand for High-Throughput Protein Analysis Growth in Biomarker Discovery and Disease Profiling Expands Applications in Oncology and Neurology Rising Adoption of Multiplexed Assays Accelerates Use in Drug Development Pipelines Integration of AI and Machine Learning Enhances Data Interpretation and Diagnostic Accuracy Expansion of Proteomics Research in Academic Institutions Drives Product Demand Technological Advancements in Microarray Surface Chemistry Strengthen Analytical Performance Growing Prevalence of Chronic Diseases Spurs Use of Protein Chips in Clinical Diagnostics Miniaturization and Automation of Laboratory Processes Propel Adoption in Research Settings Government Funding for Life Sciences R&D Supports Market Growth Across Developed Nations Partnerships Between Biotech Firms and CROs Increase Commercialization of Custom Protein Arrays Increased Interest in Immune Profiling and Vaccine Development Boosts Segment Demand Shift Toward Point-of-Care Diagnostics Expands Use of Lab-on-a-Chip Solutions Rising Throughput Requirements in Genomic-Proteomic Integration Strengthens Market Appeal Emergence of Next-Gen Antibody-Based Chips Drives Innovation and Competitive Differentiation Regulatory Advancements and Approval Pathways Facilitate Clinical Use of Protein Microarrays For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Protein Chips Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
10-06-2025
- Business
- Yahoo
Access Medical Labs, a Subsidiary of Empresas Aries, Completes Historic Lab Expansion with Roche Diagnostics Systems
Florida's largest private lab sets a new benchmark in automation, expands testing fivefold, and fuels job growth nationwide JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely achieved in the clinical laboratory industry, Access Medical Labs — the largest private diagnostic lab in Florida — has completed a full transition from Siemens to Roche Diagnostics systems in under 6 months. Such integrations typically span more than a year, making this move a breakthrough in lab automation and operational excellence. With Roche's advanced testing systems now fully deployed, Access has increased its daily diagnostic capacity fivefold. The lab can now deliver faster, more comprehensive results to functional and integrative health providers across the country.'This wasn't just a switch — it was a transformation,' said Adam El-Hosseiny, C.O.O. at Access Medical Labs. 'We brought together the right people, technology and purpose to better serve patients and providers nationwide. This technology will further solidify our role as one of the most advanced diagnostic labs in the nation.' A new model for global health collaboration The record-fast transition was driven by seamless coordination between Roche's U.S. and Mexico divisions — a cross-border collaboration that highlights the power of international cooperation in advancing medical innovation. 'This is more than a system upgrade - the total integrated solution - it's a step forward for the entire industry,' Antonio Vergara, Senior Vice President of Core Lab and Near Patient Care, Roche Diagnostics, added. 'We're proud to lead by this collective example.' Fueling the shift toward preventive, personalized care Functional and integrative medicine are gaining traction as the U.S. pivots toward preventative and personalized healthcare. Access Medical Labs works with thousands of physicians in this space, and its upgraded capabilities allow providers to access a wider menu of high-efficiency, Roche-powered assays that go beyond symptom management. This transformation comes at a pivotal time. With Dr. Casey Means — a leading voice for metabolic health — nominated as U.S. surgeon general, the national focus on proactive, data-driven medicine is intensifying. 'We believe in that future,' said Adam El-Hosseiny 'And we're building it.' Expanding teams, empowering communities Access currently employs over 200 professionals across its operations and plans to grow its workforce 35% by the end of 2025. The expansion is creating high-impact jobs in lab science, logistics, client services and med tech — reinforcing Florida's biotech economy and contributing to a more resilient healthcare workforce. 'Since 2003, we've been committed to delivering truly exceptional client experience backed by precise and reliable testing. Every innovation we pursue is driven by one purpose: making personalized medicine more practical and accessible,' said Sharif El-Hosseiny, CEO of Access. Empresas Aries is a privately-owned Mexican holding company with more than 5,000 collaborators that operates in the healthcare industry in Mexico and the US through more than 350+ patient service centers, a highly specialized hospital in Northeast Mexico, and an elementary school with education grades K-12th. Emily Pantelides Emily@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
